Position Paper: Significance of the Forced Vital Capacity in Idiopathic Pulmonary Fibrosis

被引：5

作者：

Behr, J. ^{[1
,2
]}

Bonella, F. ^{[3
]}

Bonnet, R. ^{[4
]}

Glaeser, S. ^{[5
,6
]}

Grohe, C. ^{[7
]}

Guenther, A. ^{[8
]}

Koschel, D. ^{[9
]}

Kreuter, M. ^{[10
]}

Kirsten, D. ^{[11
]}

Kroegel, C. ^{[12
]}

Markart, P. ^{[13
]}

Mueller-Quernheim, J. ^{[14
]}

Neurohr, C. ^{[15
]}

Pfeifer, M. ^{[16
]}

Prasse, A. ^{[17
]}

Schoenfeld, N. ^{[18
]}

Schreiber, J. ^{[19
]}

Wirtz, H. ^{[20
]}

Witt, C. ^{[21
]}

Costabel, U. ^{[22
]}

机构：

[1] Klinikum Univ Munchen, Med Klin & Poliklin 5, D-81377 Munich, Germany

[2] Comprehens Pneumol Ctr, Asklepios Fachkliniken Munchen Gauting, Munich, Germany

[3] Univ Klinikum Essen gGmbH, Ruhrlandklin, Westdeutsch Lungenzentrum, Essen, Germany

[4] Zentralklin Bad Berka GmbH, Abt Pneumol, Bad Berka, Germany

[5] Univ Med Greifswald, Infektiol, Klin Innere Med Bereich Pneumol B, Greifswald, Germany

[6] Univ Med Greifswald, Weaningzentrum Forsch Bereich Pneumol & Pneumol E, Greifswald, Germany

[7] Krankenhausbetriebs gGmbH, Pneumol Klin Evangel Lungenklin Berlin, Berlin, Germany

[8] Univ Gissen Marburg GmbH, Medizin Klin Pneumol & Internist Intens Med 3, Agaples Evangel Krankenhaus Mittelhessen & Schwer, Giessen, Germany

[9] Fachkrankenhaus Coswig GmbH, Abt Innere Med Pneumol, Zentrum Pneumol Allergol Beatmungsmed Thorax & Ge, Coswig, Germany

[10] Univ Kilnikum Heidelberg, Zentrum Seltene & Interstitielle, Pneumol & Beatmungsmed, Lungenerkrankungen Thoraxklin, Heidelberg, Germany

[11] Lungenclin Grosshansdorf, Grosshansdorf, Germany

[12] Klinikum Univ Jena, Med Klin 1, Abt Pneumol & Allergol Immunol, Jena, Germany

[13] Univ Klinikum Giessen & Marburg GmbH, Med Klin & Poliklin 2, Standort Giessen & Med Klin Pneumol 5, Herz Thorax Zentrum,Klinikum Fulda gAG, Giessen, Germany

[14] Univ Freiburg Klinikum, Abt Pneumol, Freiburg, Germany

[15] Klinikum Univ Munchen, Med Klin & Poliklin 5, Comprehens Pneumol Ctr, Munich, Germany

[16] Univ Regensburg, Klin Donaustauf, Klin Pneumol & Konservat Intens Med, Krankenhaus Barmherzige Bruder, D-93053 Regensburg, Germany

[17] Hannover Med Sch, Abt Pneumol, Hannover, Germany

[18] HELIOS Klinikum Emil von Behring, Lungenklin Heckeshorn, Klin Pneumol, Berlin, Germany

[19] Univ Magdeburg, Univ Klinikum, Klin Pneumol, D-39106 Magdeburg, Germany

[20] Univ Klinikum Leipzig, Abt Pneumol, Leipzig, Germany

[21] Univ Klinikum Charite, Abt Pneumol & Transplantat, Berlin, Germany

[22] Univ Klinikum Essen gGmbH, Westdeutsch Lungenzentrum, Interstitielle & Seltene Lungenkrankheiten, Ruhrlandklin, Essen, Germany

来源：

PNEUMOLOGIE | 2015年 / 69卷 / 08期

关键词：

D O I：

10.1055/s-0034-1392602

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Spirometry is a highly standardized method which allows to measure the forced vital capacity (FVC) with high precision and reproducibility. In patients with IPF FVC is directly linked to the disease process which is characterized by scaring of alveoli and shrinkage of the lungs. Consequently, there is ample evidence form clinical studies that the decline of FVC over time is consistently associated with mortality in IPF. As for the first time effective drugs for the treatment of IPF are available it becomes obvious that in studies which could demonstrate that the drug reduces FVC decline, a numerical effect on mortality was also observed, while in one study where a significant effect on FVC decline was missed, there was also no change in mortality. Based on these studies FVC decline is a validated surrogate of mortality in IPF. It is concluded that FVC decline is not only accepted as an endpoint of clinical treatment trials in IPF but is also valid as a patient related outcome parameter which should be considered for the assessment of the efficacy of an IPF drug.

引用

页码：455 / 458

页数：4

共 50 条

[1] Reference values for forced vital capacity in idiopathic pulmonary fibrosis
Pereira, Carlos A. C.
[J]. RESPIRATORY MEDICINE, 2017, 125 : 102 - 102
[2] Forced vital capacity, total lung capacity and diffusion capacity in idiopathic pulmonary fibrosis
Pesonen, Ida
Gao, Jing
Kalafatis, Dimitrios
Carlson, Lisa
Myllarniemi, Marjukka
Ferrara, Giovanni
Skold, Magnus
[J]. EUROPEAN RESPIRATORY JOURNAL, 2018, 52
[3] Different Faces of Idiopathic Pulmonary Fibrosis With Preserved Forced Vital Capacity
Bermudo, Guadalupe
Suarez-Cuartin, Guillermo
Rivera-Ortega, Pilar
Rodriguez-Portal, Jose Antonio
Sauleda, Jaume
Nunez, Belen
Castillo, Diego
Aburto, Myriam
Portillo, Karina
Balcells, Eva
Badenes-Bonet, Diana
Valenzuela, Claudia
Fernandez-Fabrellas, Estrella
Gonzalez-Budino, Teresa
Cano, Esteban
Acosta, Orlando
Leiro-Fernandez, Virginia
Romero, Ana
Planas-Cerezales, Lurdes
Villar, Ana
Moreno, Amalia
Laporta, Rosalia
Vicens-Zygmunt, Vanesa
Shull, Jessica
Franquet, Tomas
Luburich, Patricio
Molina-Molina, Maria
[J]. ARCHIVOS DE BRONCONEUMOLOGIA, 2022, 58 (02): : 135 - 141
[4] The Effect Of Bronchodilators On Forced Vital Capacity In Patients With Idiopathic Pulmonary Fibrosis
Assayag, D.
Vittinghoff, E.
Ryerson, C. J.
Cocconcelli, E.
Tonelli, R.
Elicker, B.
Golden, J.
Jones, K. D.
King, T. E.
Koth, L. L.
Lee, J. S.
Ley, B.
Wolters, P. J.
Collard, H. R.
[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
[5] Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis
Aono, Yuya
Nakamura, Yutaro
Kono, Masato
Nakamura, Hidenori
Yokomura, Koshi
Imokawa, Shiro
Toyoshima, Mikio
Yasui, Hideki
Hozumi, Hironao
Karayama, Masato
Suzuki, Yuzo
Furuhashi, Kazuki
Enomoto, Noriyuki
Fujisawa, Tomoyuki
Inui, Naoki
Suda, Takafumi
[J]. THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2020, 14
[6] Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design
Santermans, Eva
Ford, Paul
Kreuter, Michael
Verbruggen, Nadia
Meyvisch, Paul
Wuyts, Wim A.
Brown, Kevin K.
Lederer, David J.
Byrne, Adam J.
Molyneaux, Philip L.
Sivananthan, Arunon
Moor, Catharina C.
Maher, Toby M.
Wijsenbeek, Marlies
[J]. ADVANCES IN THERAPY, 2019, 36 (11) : 3059 - 3070
[7] Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis
Flaherty, Kevin R.
Kolb, Martin
Vancheri, Carlo
Tang, Wenbo
Conoscenti, Craig S.
Richeldi, Luca
[J]. EUROPEAN RESPIRATORY JOURNAL, 2018, 52 (02)
[8] Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis
Richeldi, Luca
Ryerson, Christopher J.
Lee, Joyce S.
Wolters, Paul J.
Koth, Laura L.
Ley, Brett
Elicker, Brett M.
Jones, Kirk D.
King, Talmadge E., Jr.
Ryu, Jay H.
Collard, Harold R.
[J]. THORAX, 2012, 67 (05) : 407 - 411
[9] Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design
Eva Santermans
Paul Ford
Michael Kreuter
Nadia Verbruggen
Paul Meyvisch
Wim A. Wuyts
Kevin K. Brown
David J. Lederer
Adam J. Byrne
Philip L. Molyneaux
Arunon Sivananthan
Catharina C. Moor
Toby M. Maher
Marlies Wijsenbeek
[J]. Advances in Therapy, 2019, 36 : 3059 - 3070
[10] Spirometric evaluation of idiopathic pulmonary fibrosis (IPF): forced or slow vital capacity?
Rodriguez Moncalvo, Juan Jose
Malet Ruiz, Jose
Mastroianni, Marcelo
Khoury, Marina
Caro, Fabian
[J]. EUROPEAN RESPIRATORY JOURNAL, 2019, 54

← 1 2 3 4 5 →